1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 6,60€ (+3,94%). The median is 6,44€ (+1,42%).
| Buy |
0 |
| Hold |
8 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 1,49M | 144,76% |
| Gross profit | 1,30M | 212,56% |
| Net profit | −28,50M | 21,13% |
| EBITDA | −38,49M | 66,84% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 2,34B€ |
Number of shares | 369,95M |
52-week high/low | 6,39€ - 2,80€ |
| Dividends | No |
Beta | 1,55 |
P/E ratio | −2,54 |
PEG ratio | 0,01 |
P/B ratio | 15,10 |
P/S ratio | 610,39 |
Company profile
| Name | Atai Beckley NV |
| CEO | Srinivas G. Rao |
| Headquarters | New York,
ny USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 99 |
Discover assets
Shareholders of Atai Beckley NV also invest in the following assets
